Is Nivolumab on the market?

Nivolumab (Nivolumab) was approved for medical use in the United States in 2014, and it is included on the World Health Organization’s Essential Medicines List. Nivolumab is the second systemic treatment drug for mesothelioma approved by the U.S. Food and Drug Administration (FDA) and the first immunotherapy approved by the FDA for the first-line treatment of gastric cancer. In 2015, the European Medicines Agency (EMA) decided that the benefits of nivolumab outweighed its risks, and the side effects were considered to be controllable through appropriate measures, so it was approved for marketing use.

Nivolumab, branded asOpdivo, is a drug used to treat a variety of cancers, including melanoma, lung cancer, malignant pleural mesothelioma, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial cancer, colon cancer, esophageal squamous cell carcinoma, liver cancer, stomach cancer and esophageal or gastroesophageal junction (GEJ) cancer. Nivolumab is administered as a slow intravenous injection. Nivolumab was approved by the National Medical Products Administration for marketing in China in 2018. It is the first monoclonal antibody drug targeting PD-1, and its trade name is Opdivo.

The generic drug nivolumab has not been included in medical insurance since it was launched in China. Since this drug is a strictly controlled drug, its purchase channels are restricted. Specifications The price of each box of 40mg/4ml may be around 4,000 yuan. The Turkish version of the nivolumab generic drug listed overseas may cost more than RMB 2,000 per box of 40mg/4ml (the price may fluctuate due to exchange rates). Currently, there is no generic version of nivolumab available on the market. For more drug information and specific prices, please consult a medical consultant.